Fairfield, CT – October 7, 2015 – Calmare Therapeutics Incorporated, (OTCQB: CTTC) (CTI), the Calmare® pain mitigation company, announced today that Calmare Therapeutics President and CEO Conrad Mir will be presenting the Calmare Therapeutics story at the Robins Equity Research Round-up taking place October 8-10, 2015.
The Calmare presentation is scheduled for Thursday, October 8th, at Noon PDT. The presentation will not be simulcast but rather be recorded and offered to the public for review early next week on the Catalyst website as well as Calmare Therapeutics website. The Robins Equity Research Roundup is presented by Catalyst Research Management Group –RIA.
“We are honored and thrilled to have Calmare Therapeutics participate in the Robins Equity Research Round-up and look forward to welcoming them back for years to come,” said Marc Robins CFA, president of Catalyst Research Management.
The conference is being held at the Skamania Lodge, nestled in the Cascade Range Gorge above the Columbia River. The Robins Equity Round-up is a small-cap investor conference introducing new and interesting company equities and their management team to clients and potential shareholders. The audience will include investors and brokers from the region as well as professional money managers from different parts of the country.
Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life and physical sciences, electronics, and nanotechnologies developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders.
Statements about our future expectations, including development and regulatory plans, and all other statements in this press release, other than historical facts, are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "may," "will," "should," "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our licensed technologies, growth strategies, operating performance, industry trends, and other risks and uncertainties inherent in our business, including those set forth in Item 7 under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2005, filed with the Securities and Exchange Commission ("SEC") on October 13, 2005, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.